The current study examines the results of extrahepatic biliary resection, nonoperative endoscopic biliary dilation with or without percutaneous stenting, and liver transplantation in the management of patients with primary sclerosing cholangitis (PSC).
Objective
The current study examines the results of extrahepatic biliary resection, nonoperative endoscopic biliary dilation with or without percutaneous stenting, and liver transplantation in the management of patients with primary sclerosing cholangitis (PSC).
Summary Background Data
Primary sclerosing cholangitis is a progressive inflammatory disease leading to secondary biliary cirrhosis. The most effective management of sclerosing cholangitis before the onset of cirrhosis remains unclear.
Methods
From 1980 to 1994, 146 patients with PSC were managed with either resection of the extrahepatic bile ducts and longterm transhepatic stenting (50 patients), nonoperative endoscopic biliary dilation with or without percutaneous stenting (54 patients), medical therapy (28 patients) , and/or liver transplantation (21 patients).
Results
Procedure-related morbidity and mortality rates were similar between surgically resected and nonoperatively managed patients. In noncirrhotic patients, the serum bilirubin level was significantly (p < 0.05) reduced from preoperative levels (8.3 ± 1.5 mg/dL) 1 (1.7 ± 0.4 mg/dL) and 3 (2.7 ± 0.9 mg/ dL) years after resection, but not after endoscopic or percutaneous management. For noncirrhotic PSC patients, overall 5-year survival (85% vs. 59%) and survival until death or transplantation (82% vs. 46%) were significantly longer (p < 0.05) after resection than after nonoperative dilation with or without stenting. For cirrhotic patients, survival after liver transplantation was longer than after resection or nonoperative dilation with or without stenting. Five patients developed cholangiocarcinoma, including three (6%) of the nonoperatively managed patients but none of the resected patients.
Conclusions
In carefully selected noncirrhotic patients with PSC, resection and long-term stenting remains a good option. Patients with cirrhosis should undergo liver transplantation.
Primary sclerosing cholangitis (PSC) is an idiopathic chronic inflammatory disease resulting in multifocal intraand extrahepatic biliary strictures, chronic cholestasis, and eventually cirrhosis. 1-4 Once cirrhosis develops, liver transplantation is the only therapeutic option. However Fifty-eight patients (42%) had had at least one biliary tract operation before referral. Thirty-three patients (24%) had a previous simple cholecystectomy, 25 (18%) underwent prior cholecystectomy, common bile duct exploration, and T-tube drainage, and 16 (12%) had undergone a more complex biliary reconstruction with biliary-enteric anastomosis. Forty-two patients (30%) had had a single previous biliary tract operation, whereas 16 (12%) had undergone two or more prior operations. The treatment groups did not differ significantly in any of these parameters.
Surgical Management
Fifty of the 138 patients (36%) were managed operatively, primarily with resection of the extrahepatic biliary tree and long-term transhepatic stenting. The operative technique used and early results in the initial 31 patients were reported previously.5 Preoperatively, percutaneous Ring catheters were inserted bilaterally in 19 patients and unilaterally in 19 patients to serve as technical aids at the time of exploration. Twelve patients, all early in the series, were explored without a preoperatively placed transhepatic biliary stent. In 40 patients, the extrahepatic biliary tree and hepatic duct bifurcation were resected as described previously.5 The intrahepatic biliary tree was then dilated, and 16
Fr. Silastic stents were placed, using the previously placed Ring catheters. Silastic stents were placed unilaterally in 6 patients and bilaterally in 29 patients. Five patients with a hepatic duct trifurcation had three stents placed.
Cholangiojejunostomies were then performed between individual intrahepatic ducts and a Roux-en-Y loop of jejunum. Ten patients with dominant strictures confined to the common bile duct underwent resection of the common bile duct and common hepatic duct excluding the bifurcation and hepaticojejunostomy. One patient thought pre-and intraoperatively to have pancreatic cancer underwent resection of his extrahepatic biliary tree as part of a pancreatoduodenectomy. A single right-sided transhepatic stent was placed across the anastomosis in these 10 patients. Patients managed with extrahepatic biliary resection both with and without resection of the hepatic duct bifurcation were analyzed together as one group. All resected patients were managed postoperatively with long-term transhepatic stents. Seven patients (14%) also received ursodeoxycholic acid during the postoperative period. Most of these patients were managed before 1990 (Fig. 1 
Liver Transplantation
Twenty-one patients were managed with orthotopic liver transplantation between 1988 and 1994 (see Fig. 1 ). Six of these patients were treated initially without any prior attempt at biliary drainage. Fifteen patients were transplanted after previous extrahepatic biliary resection (3 patients), endoscopic dilation (10 patients), or percutaneous stenting (2 patients). Biliary reconstruction at transplantation was performed by Roux-en-Y hepaticojejunostomy (19 patients) or choledochocholedochostomy (2 patients). Posttransplant immunosuppression consisted of prednisone, azathioprine, and cyclosporine or FK506.
Medical Management
Twenty-eight patients were managed without any invasive attempts at establishing improved biliary drainage. These patients received corticosteroids (9 patients), ursodeoxycholic acid (10 patients), and/or methotrexate (1 patient) at the discretion of their managing physician. Four Forty of the 50 surgical resection patients (80%) were noncirrhotic. Similarly, 43 of the 54 combined nonoperative patients (80%) were noncirrhotic. In comparison, only 1 of the 21 liver transplant patients (5%) did not have established cirrhosis. The surgical resection and combined nonoperative patients were also stratified by risk score. Low-risk patients had scores of 1.02 to 3.56, moderate-risk patients 3.57 to 4.82, and high-risk patients 4.87 to 6.28. The relative percentage of low-, moderate-, and high-risk patients were 44%, 40%, and 16%, respectively, for the surgical resection patients and 45%, 29%, and 26%, respectively, for the combined nonoperative patients. These differences were not statistically significant.
Indications for Treatment
The symptoms, total serum bilirubin level, and risk score at the time treatment was initiated are shown in Table 2 . Overall, 94% of the patients were symptomatic at the time treatment was initiated. All the patients undergoing surgical resection or liver transplantation were symptomatic, whereas 94% of the patients treated with endoscopic or percutaneous techniques were symptomatic. The primary indications for treatment in all groups were persistent jaundice and cholangitis. Mean total serum bilirubin levels were highest in the transplant patients ( Three of the 50 patients (6%) managed with resection of 1 days. the extrahepatic biliary tree died before discharge from the Endoscopic biliary dilation was attempted in 41 patients, hospital. All three died after a prolonged hospital course with no postprocedure mortality. A total of 119 procedures with sepsis and liver failure. All three died before 1985, and were performed in these 41 patients over a mean follow-up two of the three had cirrhosis. Operative mortality in pa-period of 26 months. Thirty-five patients were successfully tients with and without cirrhosis was 20% and 2.5%, re-dilated a mean of 3.2 times, with cholangiographic improvespectively. Postoperative complications developed in 16 ment in some of their biliary strictures. In four patients, the patients (32%) ( Table 3) . Cholangitis was the most frequent first attempt at endoscopic balloon dilation was unsuccesscomplication and occurred in five patients (10%). Four ful, and these patients were not included in the analysis of patients, including two who died, developed hemobilia re-the endoscopically managed patients. Three of these pa- tients were managed subsequently with percutaneous stenting, and one patient had no further attempts at biliary drainage. Two patients were managed with a single endoscopic dilation after removal of percutaneously placed stents and were not included with the endoscopically managed patients. The overall complication rate was only 14%, and the most common complication was mild pancreatitis, which occurred in four patients (11%) (see Table 3 ). Intraparenchymal contrast extravasation on completion cholangiography occurred in seven patients (20%). All these patients were managed expectantly with antibiotics, and none developed a biloma or abscess requiring drainage. The overall hospital stay for the initial dilation was 4 ± 0.7 days. Two hospital deaths occurred in the 19 patients (10.5%) managed with long-term percutaneous stenting. One patient with cirrhosis and cholangitis died of a variceal hemorrhage after several attempts at percutaneous biliary drainage. The second death occurred in a patient with persistent cholangitis after unsuccessful endoscopic dilation. After placement of bilateral percutaneous stents, the patient developed hemobilia requiring hepatic artery embolization. He died several days later of liver failure. The overall complication rate was 42% (see Table 3 ). A second patient with hemobilia required hepatic artery embolization, and two subphrenic abscesses were managed with percutaneous drainage. In addition, one patient had a percutaneous biliary stent placed through the transverse colon, leading to the formation of an intra-abdominal abscess. This patient was managed with operative drainage of the abscess, right hemicolectomy, and ileostomy. Since 1988, the mean hospital stay after percutaneous stent placement has been 14 ± 3 days.
Four of 21 patients (19%) died after liver transplantation. One patient died of hemorrhage from the gastroduodenal artery on the fourth postoperative day. The others died of sepsis and multiple organ failure. Eleven of the 21 patients (52%) developed postoperative complications after liver transplantation (see Table 3 ). Four 
Long-Term Results
Overall and transplant-free survival rates for the resected, endoscopically dilated, percutaneously stented, and transplanted patients are shown in Tables 5 and 6 , respectively. The 1-, 3-, 5-, and 10-year overall survival rates for all 138 PSC patients were 86%, 81%, 71%, and 56%, respectively.
The mean length of follow-up for patients managed with extrahepatic biliary resection was 62 months. Fourteen patients (28%) have died during long-term follow-up after operative resection. Nine of the late deaths after surgery were due to progressive liver failure and complications of portal hypertension. One patient died with uncontrolled sepsis and multiple hepatic abscesses. Two patients died, one early and one late, after liver transplantation. Two patients died of unrelated causes. None of the resected patients have developed cholangiocarcinoma in 3101 months of follow-up. One patient had a colon cancer resected 6 months before undergoing biliary resection and is without evidence of recurrent disease 9 years later. One of the 10 patients managed initially with a choledochojejunostomy for a dominant distal bile duct stricture developed recurrent proximal extrahepatic biliary strictures requiring reoperation, hepaticojejunostomy, and long-term transhepatic stenting. Overall 1-, 3-, 5-, and 10-year survival rates after bile duct resection were 86%, 84%, 76%, and 55%, respectively (see Table 5 ). Patients without cirrhosis fared better, with 1-, 3-, 5-, and 10-year overall survival rates of 95%, 92%, 85%, and 68%, respectively (Fig. 2) .
Seven patients (14%) underwent liver transplantation after resection of the extrahepatic biliary tree. The mean interval between resection and transplant was 63 months (range 7-139 months). Three of these transplants were other died 2 years after the transplant of chronic rejection. performed at Johns Hopkins, and four were performed else-The transplant-free survival rates at 1-, 3-, 5-, and 10 years where before 1988. Two of these patients have subsequently after extrahepatic bile duct resection were 86%, 81%, 71%, died: one died of sepsis in the perioperative period, and the and 31%, respectively (see Table 6 ). Noncirrhotic patients 91%, 80%, and 68%, respectively (see Table 5 ). Noncir-MONTHS rhotic patients had 1-, 3-, and 5-year survival rates of 88%, e 2. Overall survival for noncirrhotic patients with primary scle-72%, and 58%, respectively (see Fig. 2 tively, in the patients without cirrhosis (see Table 6 , Fig. 3 Overall survival rates at 1, 3, and 5 years after percutaneous biliary drainage were 84%, 79%, and 60%, respectively, in all patients and 87%, 79%, and 63%, respectively, in patients without cirrhosis (see Table 5 , Fig. 2 ). Three patients (16%) received liver transplants 19, 21, and 48 months after initial management with percutaneous stents. One of the patients died in the perioperative period, and two are alive 11 and 17 months after transplantation. Transplant-free survival rates at 1, 3, and 5 years were 84%, 61 %, and 49%, respectively. Transplant-free survival rates after percutaneous stenting in noncirrhotic patients were 87%, 64%, and 51% at 1, 3, and 5 years, respectively (see Table 6 , Fig. 3 ). The 3-and 5-year transplant-free survival rates were significantly lower (p < 0.05) when the percutaneously stented noncirrhotic patients were compared to their surgically managed counterparts.
Overall, 54 patients were managed with a combination of nonoperative endoscopic and percutaneous techniques. Overall and transplant-free survival rates in patients managed with nonoperative biliary drainage are shown in Tables  5 and 6 . Both overall and transplant-free survivals after extrahepatic biliary resection were significantly longer in noncirrhotic patients than after nonoperative biliary drainage. Resected and nonoperatively managed patients also were stratified into low-, moderate-, and high-risk groups according to preprocedure Mayo model risk scores (Table  7) .16 Transplant-free survival after resection was significantly longer than after nonoperative management for both low-and moderate-risk patients. No survival difference existed between treatments for high-risk patients, most of whom had cirrhosis.
Long-term survival after liver transplantation is shown in Table 5 . Four perioperative and no late deaths occurred after liver transplantation for PSC. Survival rates at 1 and 3 years after liver transplantation were both 81%. One patient developed recurrent sclerosing cholangitis 35 months after his initial transplantation and was retransplanted.
Serum bilirubin levels both before and after extrahepatic biliary resection and combined nonoperative management in noncirrhotic patients are shown in Figure 4 . Biliary resection significantly reduced serum bilirubin levels at 1, 2, Figure 4 . Serum bilirubin levels after resection and nonoperative biliary drainage. Serum bilirubin levels were significantly (p < 0.05) lower 1, 2, and 3 years after resection compared to preoperative levels. Ann. Surg. -March 1998 and 3 years after resection when compared to preoperative levels. Nonoperative biliary dilation or stenting reduced serum bilirubin levels, but this difference did not achieve statistical significance. At 1 year, none of the cirrhotic patients managed nonoperatively with endoscopic dilation or percutaneous stenting with an initial bilirubin level of 5.0 mg/dL or greater had a decrease from the initial level.
Since 1988, the initial hospital stay has been 14 ± 1 days for surgical resection compared to 4 ± 0.7 days for endoscopic dilation, 14 Table 2 ). Several centers have reported series of patients with major ductal strictures associated with PSC managed with endoscopic biliary dilation.12-14 Most patients had improvement in their predilation symptoms, and the mean serum bilirubin level was decreased in all three series after short follow-up.
Johnson et al.12 reported a persistent decrease in the serum bilirubin level 2 years after the initial dilation; this was not observed in our series. However, none of these series have examined the long-term effect of nonoperative biliary dilation on survival or the eventual need for liver transplantation.
Transplant-free survival was significantly longer after surgical resection than after either endoscopic biliary dilation or long-term percutaneous stenting. Fewer initially noncirrhotic patients (18%) had died or needed a liver transplant 5 years after biliary resection than in the 5 years after nonoperative biliary dilation (54%). Overall survival after resection was also significantly longer than after nonoperative biliary drainage. This difference was due in part to the higher incidence of cholangiocarcinoma after nonoperative therapy.
Liver transplantation is clearly the best treatment option once cirrhosis has developed. Results of nontransplant surgical treatment in cirrhotic patients were poor in our study, with a high operative mortality (20%) and a poor long-term survival rate (38% transplant-free survival at 3 years). Similar results of nontransplant surgical therapy have been reported by others in cirrhotic patients.7'0 Currently, the only indication for nontransplant operative management in the cirrhotic PSC patient is the suspicion of a cholangiocarcinoma. Results of endoscopic balloon dilation and percutaneous stenting were similar to those of resection for cirrhotic patients; neither procedure delayed the need for liver transplantation. In addition, patients with a serum bilirubin level >5.0 mg/dL and cirrhosis had no long-term decrease in their serum bilirubin level after either endoscopic dilation or percutaneous stenting. Biliary dilation is of little benefit in cirrhotic patients, except possibly in the patient with episodes of cholangitis. In patients with cholangitis and cirrhosis, endoscopic balloon dilation is safer and has a lower procedure-related mortality than percutaneous stenting.
The impact of each biliary drainage procedure on the future results of liver transplantation is an important consideration in selecting therapy for PSC patients. Several authors have expressed concern about the effect of prior biliary surgery on the morbidity and mortality of a future liver transplant.9"10'23 '24 survival remains to be seen. Similarly, whether the added mortality of early transplantation is less than the potential risk from cholangiocarcinoma has yet to be determined. None of our 50 surgically resected patients developed cholangiocarcinoma during a mean follow-up of 62 months. Natural history data suggest that seven or eight of these patients should have developed a bile duct malignancy.9 The entire extrahepatic biliary tree, including the hepatic duct bifurcation, was resected in 80% of these patients. Cholangiocarcinoma has been reported in several PSC patients after endoscopic dilation.12-14 In our series, three patients were diagnosed with cholangiocarcinoma within 25 months of the initial endoscopic dilation, underscoring the difficulty of diagnosing the disease in these patients. Two of the three patients died of their tumor. As in other series, patients were either diagnosed with incidental cholangiocarcinoma at the time of liver transplantation or with metastatic disease. Most cancers (72%) found incidentally at transplantation were at the hepatic duct bifurcation; only 1 % were intrahepatic.32 This distribution supports the potential role of bifurcation resection in lowering the risk of cholangiocarcinoma in PSC patients. The lower incidence of cholangiocarcinoma in the surgically resected patients was responsible, in part, for the greater overall survival in the noncirrhotic patients managed with this technique.
In our series, 94% of the patients, including all the patients who underwent resection and liver transplantation, had one or more signs and symptoms of PSC. Only 3 of the 54 patients (6%) managed nonoperatively were asymptomatic at the time of their initial endoscopic dilation or percutaneous stenting. Wiesner et al.3 previously demonstrated that symptomatic PSC patients have a worse prognosis than patients without symptoms. The low percentage of patients with asymptomatic PSC in this series reflects the authors' bias for the indications for treatment. This fact may also be responsible for the lower-than-predicted survival in the nonoperatively managed patients.
Resection of the hepatic duct bifurcation with long-term transhepatic stenting continues to be a good option for noncirrhotic PSC patients who have dominant extrahepatic and hilar strictures. The need for liver transplantation may be significantly delayed in this group of patients. Nonoperative biliary dilation provides symptomatic and biochemical improvement in noncirrhotic patients; however, this option provides a shorter overall and transplant-free survival than resection and may be associated with a higher incidence of cholangiocarcinoma. Liver transplantation is the therapy of choice for PSC patients once cirrhosis develops.
